Rezolute, Inc.
RZLTHealthcare|Biotechnology|US
$3.88
+0.24 (+6.59%)
DCF Value
$0.05
Tangible Book / Share
$0.82
Cash / Share
$0.86
Financials
Financial Snapshot
Market Cap
$375.3M
Enterprise Value
$367.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$77.9M
Cash & Investments
$90.0M
Net Cash
$89.2M
Free Cash Flow (TTM)
-$66.0M
Operating CF (TTM)
-$66.0M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$90.0M
Quarterly Burn
$16.5M
Monthly Burn
$5.5M
Est. Runway
~5.5 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $4.5M | $1.6M | $11.6M | $10.0M | $41.0M | $150.4M | $101.9M | $126.9M | $167.9M | $107.8M | $90.0M | |
| Operating Cash Flow | -$13.3M | -$14.1M | -$15.3M | -$24.2M | -$20.4M | -$39.6M | -$44.5M | -$57.4M | -$69.1M | -$64.6M | -$66.0M | |
| Free Cash Flow | -$13.7M | -$14.1M | -$15.4M | -$24.2M | -$20.4M | -$39.6M | -$44.6M | -$57.4M | -$69.1M | -$64.6M | -$66.0M | |
| Capital Expenditure | -$407.9K | -$5.8K | -$47.0K | $0.00 | $0.00 | $0.00 | -$153.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $13.9M | $9.5M | $25.0M | $22.6M | $51.5M | $149.0M | $11.6M | $63.0M | $107.3M | $2.2M | $1.9M |
R&D Spending
R&D (TTM)
$53.5M
R&D Intensity
—
R&D Growth vs Prior
-0.6%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $12.1M | $17.3M | $19.1M | $14.4M | $15.0M | $32.5M | $43.8M | $55.7M | $61.5M | $53.8M | $53.5M | |
| SG&A | $8.2M | $9.1M | $6.8M | $6.1M | $7.9M | $9.4M | $12.2M | $14.7M | $18.4M | $29.2M | $29.1M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $12.6M | $1.1M | $48.0K | $18.0K | $13.0K | $256.0K | $0.00 | $0.00 | $0.00 | $31.0K | $23.0K | |
| Gross Profit | -$12.6M | -$1.1M | -$48.0K | -$18.0K | -$13.0K | -$256.0K | $0.00 | $0.00 | $0.00 | -$31.0K | -$23.0K | |
| R&D | $12.1M | $17.3M | $19.1M | $14.4M | $15.0M | $32.5M | $43.8M | $55.7M | $61.5M | $53.8M | $53.5M | |
| SG&A | $8.2M | $9.1M | $6.8M | $6.1M | $7.9M | $9.4M | $12.2M | $14.7M | $18.4M | $29.2M | $29.1M | |
| Operating Income | -$20.3M | -$28.7M | -$25.9M | -$20.5M | -$22.9M | -$41.8M | -$56.0M | -$70.4M | -$79.9M | -$83.0M | -$62.3M | |
| Interest Expense | $1.6K | $689.2K | $5.0M | $0.00 | $375.0K | $1.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$20.3M | -$29.9M | -$30.4M | -$20.3M | -$20.9M | -$41.1M | -$51.8M | -$68.5M | -$74.4M | -$77.6M | -$77.9M | |
| Net Income | -$20.3M | -$29.9M | -$30.4M | -$20.3M | -$20.9M | -$41.1M | -$51.8M | -$68.5M | -$74.4M | -$77.6M | -$77.9M | |
| EPS (Diluted) | -24.55 | -26.83 | -17.11 | -3.54 | -2.72 | -2.32 | -1.01 | -1.33 | -0.98 | -0.75 | -0.76 | |
| EBITDA | -$19.2M | -$28.1M | -$25.4M | -$20.3M | -$20.5M | -$39.2M | -$51.8M | -$68.4M | -$74.4M | -$83.0M | -$79.9M | |
| Shares Out. (M) | 0.83 | 1.11 | 1.78 | 5.75 | 7.67 | 19.49 | 51.19 | 51.46 | 76.00 | 103.91 | 104.78 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.5M | $1.6M | $11.6M | $10.0M | $41.0M | $150.4M | $16.0M | $70.4M | $94.1M | $10.6M | $8.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $85.9M | $56.5M | $73.8M | $97.2M | $81.8M | |
| Total Current Assets | $4.9M | $2.0M | $12.1M | $10.5M | $42.0M | $152.1M | $104.9M | $128.7M | $171.1M | $107.8M | $93.8M | |
| Total Assets | $10.6M | $2.5M | $12.3M | $11.0M | $42.6M | $152.4M | $123.7M | $132.7M | $175.5M | $112.8M | $96.0M | |
| Total Current Liabilities | $1.8M | $6.2M | $8.4M | $3.2M | $2.0M | $2.5M | $5.2M | $9.6M | $11.9M | $11.4M | $9.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $14.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $111.0K | |
| Total Liabilities | $2.1M | $6.5M | $10.5M | $3.6M | $16.5M | $2.9M | $7.5M | $11.7M | $13.4M | $12.2M | $10.1M | |
| Stockholders' Equity | $8.5M | -$4.0M | $1.8M | $7.4M | $26.1M | $149.5M | $116.2M | $121.0M | $162.1M | $100.7M | $85.9M | |
| Retained Earnings | -$64.3M | -$94.2M | -$126.9M | -$147.2M | -$168.1M | -$209.2M | -$261.0M | -$329.4M | -$403.9M | -$481.4M | -$499.9M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.3M | -$14.1M | -$15.3M | -$24.2M | -$20.4M | -$39.6M | -$44.5M | -$57.4M | -$69.1M | -$64.6M | -$66.0M | |
| Capital Expenditure | -$407.9K | -$5.8K | -$47.0K | $0.00 | $0.00 | $0.00 | -$153.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$13.7M | -$14.1M | -$15.4M | -$24.2M | -$20.4M | -$39.6M | -$44.6M | -$57.4M | -$69.1M | -$64.6M | -$66.0M | |
| Investing Cash Flow | -$195.4K | $1.7M | $231.0K | $0.00 | $0.00 | $0.00 | -$101.5M | $48.7M | -$14.5M | -$21.1M | $63.2M | |
| Financing Cash Flow | $13.9M | $9.5M | $25.0M | $22.6M | $51.5M | $149.0M | $11.6M | $63.0M | $107.3M | $2.2M | $1.9M | |
| Issuance of Stock | $14.6M | $4.5M | $0.00 | $24.1M | $41.0M | $122.8M | $12.3M | $49.0M | $107.3M | $2.2M | $1.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$23.1K | $5.3M | $0.00 | $0.00 | $15.0M | -$16.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.0M | $5.1M | $2.6M | $3.3M | $4.0M | $3.7M | $7.3M | $7.4M | $7.1M | $14.5M | $11.1M | |
| Net Change in Cash | $424.5K | -$2.8M | $9.9M | -$1.6M | $31.1M | $109.4M | -$134.4M | $54.4M | $23.7M | -$83.5M | -$948.0K |
Dilution Tracker
Shares outstanding grew 1254.5% over 5 years — significant dilution
Shares Outstanding
97M
5-Year Share Growth
+1254.5%
Stock Issuance (TTM)
$1.3M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.83 | 1.11 | 1.78 | 5.75 | 7.67 | 19.49 | 51.19 | 51.46 | 76.00 | 103.91 | 104.78 | |
| Change vs Prior % | — | 34.8% | 59.7% | 223.6% | 33.4% | 154.0% | 162.7% | 0.5% | 47.7% | 36.7% | 0.8% | |
| Stock Issuance | $14.6M | $4.5M | $0.00 | $24.1M | $41.0M | $122.8M | $12.3M | $49.0M | $107.3M | $2.2M | $1.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $6.0M | $5.1M | $2.6M | $3.3M | $4.0M | $3.7M | $7.3M | $7.4M | $7.1M | $14.5M | $11.1M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -237.8% | 753.9% | -1736.1% | -276.1% | -80.1% | -27.5% | -44.6% | -56.6% | -45.9% | -77.1% | -72.2% | |
| ROA % | -190.8% | -1193.1% | -248.3% | -185.4% | -49.1% | -26.9% | -41.9% | -51.6% | -42.4% | -68.8% | -81.2% | |
| ROIC % | -229.1% | 9265.2% | -667.5% | -257.0% | -56.0% | -27.9% | -47.0% | -56.9% | -48.7% | -81.3% | -71.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | -52.1% | 91.5% | 95.5% | 62.5% | 27.8% | -1869.2% | 100.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -35.9% | -41.4% | 9.7% | 20.9% | -11.6% | -82.8% | -33.8% | -25.8% | -13.4% | -3.8% | |
| Net Income | -35.8% | -47.3% | -1.9% | 33.2% | -2.8% | -96.4% | -26.1% | -32.2% | -8.7% | -4.3% | |
| EPS (Diluted) | 18.5% | -9.3% | 36.2% | 79.3% | 23.2% | 14.7% | 56.5% | -31.7% | 26.3% | 23.5% | |
| Operating Cash Flow | -26.9% | -6.0% | -8.4% | -57.9% | 15.4% | -93.8% | -12.3% | -29.0% | -20.4% | 6.4% | |
| Free Cash Flow | -9.1% | -2.9% | -8.7% | -57.4% | 15.4% | -93.8% | -12.7% | -28.5% | -20.4% | 6.4% | |
| R&D Expense | 28.0% | 42.9% | 10.4% | -24.3% | 3.7% | 116.8% | 34.9% | 27.2% | 10.4% | -12.6% | |
| SG&A Expense | 49.5% | 10.6% | -25.1% | -11.0% | 30.2% | 18.3% | 30.1% | 20.6% | 25.1% | 58.8% | |
| Total Assets | -2.5% | -76.5% | 389.5% | -10.5% | 288.6% | 257.7% | -18.8% | 7.3% | 32.2% | -35.7% | |
| Book Value / Share | -41.7% | -134.5% | 127.7% | 29.9% | 165.7% | 141.4% | -72.4% | 3.6% | -9.3% | -54.6% | |
| Debt | -88.0% | 34246.1% | -99.7% | 4000.0% | 3417.1% | -98.7% | 1218.1% | -10.1% | -27.5% | -42.2% | |
| Diluted Shares | 66.7% | 34.8% | 59.7% | 223.6% | 33.4% | 154.0% | 162.7% | 0.5% | 47.7% | 36.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B4.73
10Y Low / Med / High0.39 / 3.63 / 10.04
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.05
Tangible Book / Share
$0.82
Net Current Assets / Share
$0.87
Graham Net-Net
$0.76
Cash / Share
$0.86
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -2.30 | -0.84 | -0.58 | -1.31 | -5.25 | -1.43 | -1.96 | -3.24 | -4.55 | -6.93 | -5.11 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 5.47 | -6.32 | 10.04 | 3.63 | 4.19 | 0.39 | 0.87 | 1.83 | 2.09 | 5.37 | 4.73 | |
| EV/EBITDA | -2.20 | -0.95 | -0.24 | -0.85 | -4.04 | 2.33 | -1.70 | -2.25 | -3.31 | -6.40 | -4.61 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
13.40
Safe
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $2.6M | $54.1M | $155.7M |
| Net Income | -$77.9M | -$54.0M | $32.6M |
| EPS | $-0.71 | $-0.52 | $-0.61 |
| # Analysts (EPS) | 5 | 6 | 8 |